Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Characterizing Treatment Patterns and Healthcare Use in Patients and Subgroups with Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Real-World Study

HP. Hartung, N. Atassi, M. Alonso-Alonso, M. Nunez, A. Seluzhytsky, E. Smolkina, F. Dormont, M. Lopez-Grancha, O. Saeed, M. Nguyen, R. Lewis

. 2026 ; 15 (1) : 269-286. [pub] 20251128

Status neindexováno Jazyk angličtina Země Nový Zéland

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc26001549

INTRODUCTION: Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare autoimmune disorder of the peripheral nervous system. While some patients with CIDP respond to standard-of-care treatments, a significant proportion remains refractory or has partial response. Evidence on the disease burden of this patient group is limited. This retrospective study aimed to analyze the demographics, clinical characteristics, and healthcare resource use of patients with CIDP in the United States, focusing on those who switched therapies within 2 years of initiating first-line treatment (LOT1). METHODS: Integrated data from the Optum® de-identified Market Clarity dataset were used to identify adults diagnosed with CIDP from 2008-2020. RESULTS: The CIDP cohort included 1942 treated patients (54% male, 75% aged ≥ 50 years). LOT1 included immunoglobulins (43%), corticosteroids (32%), combination of immunoglobulins and corticosteroids (11%), immunosuppressants (10%), and plasma exchange (5%). Within 2 years, 31% patients switched to second-line treatment (LOT2). The median time to switch from LOT1 to LOT2 was 5.6 months. Within 2 years after initiating LOT1, 92% patients had outpatient visits and 40% were hospitalized. Patients who switched treatments had more healthcare visits than those who did not switch (45.3 vs. 35.3/year). CONCLUSION: Approximately one-third of the patients switched to a new treatment within 2 years after starting treatment, which could be partly due to limited efficacy of therapies in LOT1. The decrease in treatment duration after LOT1 may suggest limited utility of subsequent therapies. Frequent treatment changes and increased healthcare encounters in this subgroup highlight significant unmet needs in CIDP.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc26001549
003      
CZ-PrNML
005      
20260122082552.0
007      
ta
008      
260116s2026 nz f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s40120-025-00862-3 $2 doi
035    __
$a (PubMed)41313584
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a nz
100    1_
$a Hartung, Hans-Peter $u Department of Neurology, Faculty of Medicine, Heinrich Heine University, Düsseldorf, Germany $u Brain and Mind Centre, University of Sydney, Sydney, NSW, Australia $u Department of Neurology, Palacký University, Olomouc, Czech Republic
245    10
$a Characterizing Treatment Patterns and Healthcare Use in Patients and Subgroups with Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Real-World Study / $c HP. Hartung, N. Atassi, M. Alonso-Alonso, M. Nunez, A. Seluzhytsky, E. Smolkina, F. Dormont, M. Lopez-Grancha, O. Saeed, M. Nguyen, R. Lewis
520    9_
$a INTRODUCTION: Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare autoimmune disorder of the peripheral nervous system. While some patients with CIDP respond to standard-of-care treatments, a significant proportion remains refractory or has partial response. Evidence on the disease burden of this patient group is limited. This retrospective study aimed to analyze the demographics, clinical characteristics, and healthcare resource use of patients with CIDP in the United States, focusing on those who switched therapies within 2 years of initiating first-line treatment (LOT1). METHODS: Integrated data from the Optum® de-identified Market Clarity dataset were used to identify adults diagnosed with CIDP from 2008-2020. RESULTS: The CIDP cohort included 1942 treated patients (54% male, 75% aged ≥ 50 years). LOT1 included immunoglobulins (43%), corticosteroids (32%), combination of immunoglobulins and corticosteroids (11%), immunosuppressants (10%), and plasma exchange (5%). Within 2 years, 31% patients switched to second-line treatment (LOT2). The median time to switch from LOT1 to LOT2 was 5.6 months. Within 2 years after initiating LOT1, 92% patients had outpatient visits and 40% were hospitalized. Patients who switched treatments had more healthcare visits than those who did not switch (45.3 vs. 35.3/year). CONCLUSION: Approximately one-third of the patients switched to a new treatment within 2 years after starting treatment, which could be partly due to limited efficacy of therapies in LOT1. The decrease in treatment duration after LOT1 may suggest limited utility of subsequent therapies. Frequent treatment changes and increased healthcare encounters in this subgroup highlight significant unmet needs in CIDP.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Atassi, Nazem $u Sanofi, Cambridge, MA, USA
700    1_
$a Alonso-Alonso, Miguel $u Sanofi, Cambridge, MA, USA
700    1_
$a Nunez, Manuel $u Sanofi, Cambridge, MA, USA
700    1_
$a Seluzhytsky, Alex $u Sanofi, Cambridge, MA, USA
700    1_
$a Smolkina, Ekaterina $u Sanofi, Amsterdam, The Netherlands. Ekaterina.Smolkina@sanofi.com
700    1_
$a Dormont, Flavio $u Sanofi, Cambridge, MA, USA
700    1_
$a Lopez-Grancha, Mati $u Sanofi, Gentilly, Paris, France
700    1_
$a Saeed, Omar $u Sanofi, Reading, UK
700    1_
$a Nguyen, Marvin $u Sanofi, Cambridge, MA, USA $u Daiichi Sankyo, Basking Ridge, NJ, USA
700    1_
$a Lewis, Richard $u Cedars-Sinai Medical Center, Los Angeles, CA, USA
773    0_
$w MED00188796 $t Neurology and therapy $x 2193-8253 $g Roč. 15, č. 1 (2026), s. 269-286
856    41
$u https://pubmed.ncbi.nlm.nih.gov/41313584 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20260116 $b ABA008
991    __
$a 20260122082537 $b ABA008
999    __
$a ok $b bmc $g 2470200 $s 1267266
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2026 $b 15 $c 1 $d 269-286 $e 20251128 $i 2193-8253 $m Neurology and therapy $n Neurol Ther $x MED00188796
LZP    __
$a Pubmed-20260116

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace